FDMT

4D Molecular Therapeutics, Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

FDMT4D Molecular Therapeutics
0Calm
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Running, no new patientsPhase 3480 patientsMain results: Jun 2027
FDMT4D Molecular Therapeutics
0Calm
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Signing up patientsPhase 3480 patientsMain results: Nov 2027

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

19 sales (0 not pre-planned) · 0 purchases

Bizily ScottChief Legal Officer · Oct 16, 2026Sold 1,635 sharesabout $21 thousand · pre-planned
Kirn DavidSee Remarks · Oct 5, 2026Sold 58,061 sharesabout $750 thousand · pre-planned
Kirn DavidSee Remarks · Oct 5, 2026Sold 272 sharesabout $4 thousand · pre-planned
Bizily ScottChief Legal Officer · Sep 16, 2026Sold 1,635 sharesabout $22 thousand · pre-planned
Kirn DavidSee Remarks · Sep 14, 2026Sold 58,333 sharesabout $811 thousand · pre-planned
Bizily ScottChief Legal Officer · Sep 1, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.